Cuál es la primera manifestación en mujeres y en hombres | 01 DIC 14

Riesgo cardiovascular: diferencias según el sexo

Dos de cada tres hombres y mujeres de 55 años padecerán enfermedad cardiovascular durante los años que les quedan de vida. Los resultados de este estudio señalan la importancia del control adecuado de los factores de riesgo para el accidente cerebrovascular y la insuficiencia cardíaca.
INDICE:  1. Desarrollo | 2. Referencias
Referencias

REFERENCIAS

1 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 2014; 129:e28-292.
2 Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, et al. European cardiovascular disease statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis, 2012.
3 Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89-92.
4 Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 2009; 40:1032-7.
5 Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106:3068-72.
6 Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study. Eur Heart J 2004; 25:1614-9.
7 Lloyd-Jones DM, Dyer AR, Wang R, Daviglus ML, Greenland P. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). Am J Cardiol 2007; 99:535-40.
8 Störk S, Feelders RA, van den Beld AW, Steyerberg EW, Savelkoul HFJ, Lamberts SWJ, et al. Prediction of mortality risk in the elderly. Am J Med 2006; 119:519-25.
9 Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7: 403-22.
10 Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013; 28:889-926.
11 Hofman A, Boerlage PA, Bots ML, den Breeijen JH, de Bruijn AM, Grobbee DE, et al. [De prevalentie van chronische ziekten bij ouderen; het ERGO-onderzoek]. Ned Tijdschr Geneeskd 1995; 139:1975-8.
12 Leening MJG, Kavousi M, Heeringa J, van Rooij FJA, Verkroost-van Heemst J, Deckers JW, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 2012; 27:173-85.
13 Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MMB. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol 2012; 27:287-95.
14 Bos MJ, van Rijn MJE, Witteman JCM, Hofman A, Koudstaal PJ, Breteler MMB. Incidence and prognosis of transient neurological attacks. JAMA 2007; 298:2877-85.
15 Koller MT, Leening MJG, Wolbers M, Steyerberg EW, Hunink MGM, Schoop R, et al. Development and validation of a coronary risk prediction model for older U.S. and European persons in the Cardiovascular Health Study and the Rotterdam Study. Ann Intern Med 2012; 157:389-97.
16 Kavousi M, Elias-Smale SE, Rutten JHW, Leening MJG, Vliegenthart R, Verwoert GC, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012; 156:438-44.
17 Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91:1229-35.
18 Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26:2389-430.
19 Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies—analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 2008; 26:31-5.
20 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
21 Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-32.
22 Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM Algorithm. J R Stat Soc B 1977; 39:1-38.
23 Wilkins JT, Ning H, Berry JD, Zhao L, Dyer AR, Lloyd-Jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA 2012; 308:1795-801.
24 Hernán MA. The hazards of hazard ratios. Epidemiology 2010; 21:13-5.
25 JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100(suppl 2):ii1-ii67.
26 Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 suppl 2):S49-73.
27 Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham Heart Study general cardiovascular risk profile. Circulation 2009; 120:384-90.
28 Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, et al. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation 2012; 125:1748-56, S1-11.
29 Michos ED, Blumenthal RS. How accurate are 3 risk prediction models in US women? Circulation 2012; 125:1723-6.
30 Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
31 Perk J, De Backer G, Gohlke H, Graham IM, Reiner Z, Verschuren WMM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33:1635-701.
32 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 suppl 2):S1-45.
33 Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311:1416-23.
34 Bos MJ, Koudstaal PJ, Hofman A, Ikram MA. Modifiable etiological factors and the burden of stroke from the Rotterdam Study: a population-based cohort study. PLoS Med 2014; 11:e1001634.
35 He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996-1002.
36 Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, et al. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013; 61:1510-7.
37 Butler J, Kalogeropoulos AP, Georgiopoulou VV, Bibbins-Domingo K, Najjar SS, Sutton-Tyrrell KC, et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011; 97:1304-11.
38 Ferket BS, van Kempen BJH, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RLG, et al. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. PLoS Med 2012; 9:e1001361.
39 Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA 2013; 310:2609-10.
40 Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd-Jones DM. Racial differences in risks for first cardiovascular events and noncardiovascular death: the atherosclerosis risk in communities study, the cardiovascular health study, and the multi-ethnic study of atherosclerosis. Circulation 2012; 126:50-9.
41 Leening MJG, Heeringa J, Deckers JW, Franco OH, Hofman A, Witteman JCM, et al. Healthy volunteer effect and cardiovascular risk. Epidemiology 2014; 25:470-1.
42 Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA 2012; 307:813-22

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024